The leading market experts have placed a mean price target of $69.95 on Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock. This price level, which is estimated to be attained in one-year, indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $1.46 a share for the upcoming quarter and $5.29 for the current fiscal.
The technical analysis of Teva Pharmaceutical Industries plainly substantiates that the 50-day moving average of Teva Pharmaceutical Industries is $52.73, and stock is trading $0.78 points away or +1.49% from its 50-day moving average of $52.73. Further it is trading $-1.07 or -1.97% away its 200-day moving average of $54.58. Teva Pharmaceutical Industries Limited (NYSE:TEVA) 52-week high is $70.09 and the 52-week low is $48.01.
This explains if the stock moves $-16.58, it will post a 52-week high. In event of +11.46% decline, a 52-week low will be hit.
Taking the valuation aspect to emphasize the valuation of Teva Pharmaceutical Industries , shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Teva Pharmaceutical Industries Limited (NYSE:TEVA) ratio came in at 35.74.
The stock last ended the trading session at $53.51 and registered a market cap of $48.91B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Teva Pharmaceutical Industries Limited (NYSE:TEVA) PEG ratio is at 1.75.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...